Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.
Publication
, Journal Article
Branche, AR; Rouphael, NG; Losada, C; Baden, LR; Anderson, EJ; Luetkemeyer, AF; Diemert, DJ; Winokur, PL; Presti, RM; Kottkamp, AC; Falsey, AR ...
Published in: Clin Infect Dis
August 22, 2023
In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Infect Dis
DOI
EISSN
1537-6591
Publication Date
August 22, 2023
Volume
77
Issue
4
Start / End Page
560 / 564
Location
United States
Related Subject Headings
- Vaccines, Combined
- SARS-CoV-2
- Microbiology
- Humans
- COVID-19
- Antibodies, Viral
- Antibodies, Neutralizing
- 3202 Clinical sciences
- 11 Medical and Health Sciences
- 06 Biological Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Branche, A. R., Rouphael, N. G., Losada, C., Baden, L. R., Anderson, E. J., Luetkemeyer, A. F., … Beigel, J. H. (2023). Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial. Clin Infect Dis, 77(4), 560–564. https://doi.org/10.1093/cid/ciad209
Branche, Angela R., Nadine G. Rouphael, Cecilia Losada, Lindsey R. Baden, Evan J. Anderson, Anne F. Luetkemeyer, David J. Diemert, et al. “Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.” Clin Infect Dis 77, no. 4 (August 22, 2023): 560–64. https://doi.org/10.1093/cid/ciad209.
Branche AR, Rouphael NG, Losada C, Baden LR, Anderson EJ, Luetkemeyer AF, et al. Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial. Clin Infect Dis. 2023 Aug 22;77(4):560–4.
Branche, Angela R., et al. “Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.” Clin Infect Dis, vol. 77, no. 4, Aug. 2023, pp. 560–64. Pubmed, doi:10.1093/cid/ciad209.
Branche AR, Rouphael NG, Losada C, Baden LR, Anderson EJ, Luetkemeyer AF, Diemert DJ, Winokur PL, Presti RM, Kottkamp AC, Falsey AR, Frey SE, Rupp R, Bäcker M, Novak RM, Walter EB, Jackson LA, Little SJ, Immergluck LC, Mahgoub SM, Whitaker JA, Babu TM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Netzl A, Smith DJ, Telu K, Mu J, Makowski M, Makhene MK, Crandon S, Montefiori DC, Roberts PC, Beigel JH. Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial. Clin Infect Dis. 2023 Aug 22;77(4):560–564.
Published In
Clin Infect Dis
DOI
EISSN
1537-6591
Publication Date
August 22, 2023
Volume
77
Issue
4
Start / End Page
560 / 564
Location
United States
Related Subject Headings
- Vaccines, Combined
- SARS-CoV-2
- Microbiology
- Humans
- COVID-19
- Antibodies, Viral
- Antibodies, Neutralizing
- 3202 Clinical sciences
- 11 Medical and Health Sciences
- 06 Biological Sciences